1M3Q
| |
4N9F
| Crystal structure of the Vif-CBFbeta-CUL5-ElOB-ElOC pentameric complex | Descriptor: | Core-binding factor subunit beta, Cullin-5, Transcription elongation factor B polypeptide 1, ... | Authors: | Guo, Y.Y, Dong, L.Y, Huang, Z.W. | Deposit date: | 2013-10-21 | Release date: | 2014-01-08 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (3.3 Å) | Cite: | Structural basis for hijacking CBF-b and CUL5 E3 ligase complex by HIV-1 Vif Nature, 505, 2014
|
|
4AA5
| P38ALPHA MAP KINASE BOUND TO CMPD 33 | Descriptor: | MITOGEN-ACTIVATED PROTEIN KINASE 14, N-CYCLOPROPYL-4-METHYL-3-[6-(4-METHYLPIPERAZIN-1-YL)-4-OXIDANYLIDENE-QUINAZOLIN-3-YL]BENZAMIDE | Authors: | Gerhardt, S, Hargreaves, D. | Deposit date: | 2011-11-30 | Release date: | 2012-05-16 | Last modified: | 2019-02-06 | Method: | X-RAY DIFFRACTION (2.38 Å) | Cite: | The Discovery of N-Cyclopropyl-4-Methyl-3-[6--(4-Methylpiperazin-1-Yl-4-Oxoquinazolin-3(4H)-Yl]Benzamide (Azd6703), a Clinical P38Alpha Map Kinase Inhibitor for the Treatment of Inflammatory Diseases Bioorg.Med.Chem.Lett., 22, 2012
|
|
6M7A
| |
4EH8
| Human p38 MAP kinase in complex with NP-F7 and RL87 | Descriptor: | Mitogen-activated protein kinase 14, N~4~-cyclopropyl-2-phenylquinazoline-4,7-diamine, [3-(benzyloxy)phenyl]methanol | Authors: | Over, B, Gruetter, C, Waldmann, H, Rauh, D. | Deposit date: | 2012-04-02 | Release date: | 2012-12-05 | Last modified: | 2023-09-13 | Method: | X-RAY DIFFRACTION (2.2 Å) | Cite: | Natural-product-derived fragments for fragment-based ligand discovery. Nat Chem, 5, 2012
|
|
1Z5S
| Crystal structure of a complex between UBC9, SUMO-1, RANGAP1 and NUP358/RANBP2 | Descriptor: | Ran GTPase-activating protein 1, Ran-binding protein 2, Ubiquitin-conjugating enzyme E2 I, ... | Authors: | Reverter, D, Lima, C.D. | Deposit date: | 2005-03-19 | Release date: | 2005-06-07 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (3.01 Å) | Cite: | Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex. Nature, 435, 2005
|
|
6M7B
| |
6OPH
| phosphorylated ERK2 with GDC-0994 | Descriptor: | 1-[(1~{S})-1-(4-chloranyl-3-fluoranyl-phenyl)-2-oxidanyl-ethyl]-4-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]pyridin-2-one, Mitogen-activated protein kinase 1 | Authors: | Vigers, G.P, Smith, D. | Deposit date: | 2019-04-25 | Release date: | 2019-07-31 | Last modified: | 2023-11-15 | Method: | X-RAY DIFFRACTION (2.4 Å) | Cite: | Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2. Proc.Natl.Acad.Sci.USA, 116, 2019
|
|
1I3W
| ACTINOMYCIN D BINDING TO CGATCGATCG | Descriptor: | 5'-D(*C*GP*AP*TP*CP*GP*AP*(BRU)P*CP*GP)-3', ACTINOMYCIN D | Authors: | Robinson, H, Gao, Y.-G, Yang, X.-L, Sanishvili, R, Joachimiak, A, Wang, A.H.-J. | Deposit date: | 2001-02-17 | Release date: | 2001-05-21 | Last modified: | 2024-07-10 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | Crystallographic Analysis of a Novel Complex of Actinomycin D Bound to the DNA Decamer Cgatcgatcg. Biochemistry, 40, 2001
|
|
6OT6
| Rat ERK2 D319N | Descriptor: | Mitogen-activated protein kinase 1, SULFATE ION | Authors: | Taylor, C.A, Goldsmith, E.J, Cobb, M.H. | Deposit date: | 2019-05-02 | Release date: | 2019-07-10 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (1.65 Å) | Cite: | Functional divergence caused by mutations in an energetic hotspot in ERK2. Proc.Natl.Acad.Sci.USA, 116, 2019
|
|
5BUI
| ERK2 complexed with 2-pyridiyl tetrahydroazaindazole | Descriptor: | 3-(4-fluorophenyl)-5-(pyridin-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine, Mitogen-activated protein kinase 1, NICKEL (II) ION | Authors: | Bellamacina, C.R, Shu, W, Bussiere, D.E, Bagdanoff, J.T. | Deposit date: | 2015-06-03 | Release date: | 2015-07-15 | Last modified: | 2023-09-27 | Method: | X-RAY DIFFRACTION (2.12 Å) | Cite: | Ligand efficient tetrahydro-pyrazolopyridines as inhibitors of ERK2 kinase. Bioorg.Med.Chem.Lett., 25, 2015
|
|
6OPG
| phosphorylated ERK2 with AMP-PNP | Descriptor: | MAGNESIUM ION, Mitogen-activated protein kinase 1, PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER | Authors: | Vigers, G.P, Smith, D. | Deposit date: | 2019-04-25 | Release date: | 2019-07-31 | Last modified: | 2023-11-15 | Method: | X-RAY DIFFRACTION (2.9 Å) | Cite: | Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2. Proc.Natl.Acad.Sci.USA, 116, 2019
|
|
2F8X
| Crystal structure of activated Notch, CSL and MAML on HES-1 promoter DNA sequence | Descriptor: | 5'-D(*GP*TP*TP*AP*CP*TP*GP*TP*GP*GP*GP*AP*AP*AP*GP*AP*AP*A)-3', 5'-D(*TP*TP*TP*CP*TP*TP*TP*CP*CP*CP*AP*CP*AP*GP*TP*AP*AP*C)-3', Mastermind-like protein 1, ... | Authors: | Nam, Y, Sliz, P, Blacklow, S.C. | Deposit date: | 2005-12-04 | Release date: | 2006-04-04 | Last modified: | 2023-08-30 | Method: | X-RAY DIFFRACTION (3.25 Å) | Cite: | Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell(Cambridge,Mass.), 124, 2006
|
|
7VV9
| |
5BUE
| ERK2 complexed with N-benzylpyridone tetrahydroazaindazole | Descriptor: | 1-benzyl-4-[3-(pyridin-4-yl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]pyridin-2(1H)-one, Mitogen-activated protein kinase 1, NICKEL (II) ION | Authors: | Bellamacina, C.R, Shu, W, Bussiere, D.E, Bagdanoff, J.T. | Deposit date: | 2015-06-03 | Release date: | 2015-07-15 | Last modified: | 2024-03-06 | Method: | X-RAY DIFFRACTION (2.4 Å) | Cite: | Ligand efficient tetrahydro-pyrazolopyridines as inhibitors of ERK2 kinase. Bioorg.Med.Chem.Lett., 25, 2015
|
|
4GEO
| P38a MAP kinase DEF-pocket penta mutant (M194A, L195A, H228A, I229A, Y258A) | Descriptor: | Mitogen-activated protein kinase 14, octyl beta-D-glucopyranoside | Authors: | Livnah, O, Tzarum, N. | Deposit date: | 2012-08-02 | Release date: | 2013-05-22 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (1.66 Å) | Cite: | P38a MAP kinase DEF-pocket penta mutant (M194A, L195A, H228A, I229A, Y258A) To be Published
|
|
5BVF
| Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase | Descriptor: | 2-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-8-(2-{[(1S,3R)-3-hydroxycyclopentyl]amino}pyrimidin-4-yl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one, Mitogen-activated protein kinase 1, SULFATE ION | Authors: | Ma, X, Steven, S. | Deposit date: | 2015-06-05 | Release date: | 2015-09-09 | Last modified: | 2023-09-27 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase. Bioorg.Med.Chem.Lett., 25, 2015
|
|
6OPK
| Phosphorylated ERK2 with Vertex-11e | Descriptor: | 4-{2-[(2-chloro-4-fluorophenyl)amino]-5-methylpyrimidin-4-yl}-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide, Mitogen-activated protein kinase 1 | Authors: | Vigers, G.P, Rudolph, J. | Deposit date: | 2019-04-25 | Release date: | 2019-07-31 | Last modified: | 2023-11-15 | Method: | X-RAY DIFFRACTION (2.54 Å) | Cite: | Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2. Proc.Natl.Acad.Sci.USA, 116, 2019
|
|
6OTS
| Rat ERK2 E320K | Descriptor: | Mitogen-activated protein kinase 1 | Authors: | Taylor, C.A, Cormier, K.W, Juang, Y.-C, Goldsmith, E.J, Cobb, M.H. | Deposit date: | 2019-05-03 | Release date: | 2019-07-10 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (2.1 Å) | Cite: | Functional divergence caused by mutations in an energetic hotspot in ERK2. Proc.Natl.Acad.Sci.USA, 116, 2019
|
|
4XJ0
| Crystal structure of ERK2 in complex with an inhibitor 14K | Descriptor: | 1-[(1S)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-4-yl]pyridin-2(1H)-one, Mitogen-activated protein kinase 1 | Authors: | Yin, J, Wang, W. | Deposit date: | 2015-01-08 | Release date: | 2015-09-16 | Last modified: | 2023-09-27 | Method: | X-RAY DIFFRACTION (2.58 Å) | Cite: | Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2. J.Med.Chem., 58, 2015
|
|
1WLJ
| human ISG20 | Descriptor: | ACETATE ION, MANGANESE (II) ION, URIDINE-5'-MONOPHOSPHATE, ... | Authors: | Horio, T, Murai, M, Inoue, T, Hamasaki, T, Tanaka, T, Ohgi, T. | Deposit date: | 2004-06-28 | Release date: | 2004-12-21 | Last modified: | 2024-03-13 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Crystal structure of human ISG20, an interferon-induced antiviral ribonuclease Febs Lett., 577, 2004
|
|
6F3T
| Crystal structure of the human TAF5-TAF6-TAF9 complex | Descriptor: | CHLORIDE ION, Transcription initiation factor TFIID subunit 5, Transcription initiation factor TFIID subunit 6, ... | Authors: | Haffke, M, Berger, I. | Deposit date: | 2017-11-28 | Release date: | 2018-12-05 | Last modified: | 2018-12-19 | Method: | X-RAY DIFFRACTION (2.5 Å) | Cite: | Chaperonin CCT checkpoint function in basal transcription factor TFIID assembly. Nat. Struct. Mol. Biol., 25, 2018
|
|
8H3Q
| Cryo-EM Structure of the CAND1-Cul3-Rbx1 complex | Descriptor: | Cullin-3, Cullin-associated NEDD8-dissociated protein 1, E3 ubiquitin-protein ligase RBX1, ... | Authors: | Hu, Y, Mao, Q, Chen, Z, Sun, L. | Deposit date: | 2022-10-09 | Release date: | 2023-10-11 | Last modified: | 2024-03-20 | Method: | ELECTRON MICROSCOPY (3.76 Å) | Cite: | Dynamic molecular architecture and substrate recruitment of cullin3-RING E3 ligase CRL3 KBTBD2. Nat.Struct.Mol.Biol., 31, 2024
|
|
6NIF
| crystal structure of human REV7-RAN complex | Descriptor: | hREV7, GTP-binding nuclear protein Ran, hREV3 fusion | Authors: | Wang, X, Pertz, L, Hua, D.P, Zhang, T.Q, Listovsky, T, Xie, W. | Deposit date: | 2018-12-27 | Release date: | 2019-09-11 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (2.002 Å) | Cite: | REV7 has a dynamic adaptor region to accommodate small GTPase RAN/ShigellaIpaB ligands, and its activity is regulated by the RanGTP/GDP switch. J.Biol.Chem., 294, 2019
|
|
4ZXT
| Complex of ERK2 with catechol | Descriptor: | AMMONIUM ION, CATECHOL, Mitogen-activated protein kinase 1, ... | Authors: | Kurinov, I, Malakhova, M. | Deposit date: | 2015-05-20 | Release date: | 2016-05-25 | Last modified: | 2016-10-05 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | A natural small molecule, catechol, induces c-Myc degradation by directly targeting ERK2 in lung cancer. Oncotarget, 7, 2016
|
|